Case Report: Immune-mediated Complete Response in a Patient With Recurrent Advanced Ewing Sarcoma (EWS) After Vigil Immunotherapy

J Pediatr Hematol Oncol. 2017 May;39(4):e183-e186. doi: 10.1097/MPH.0000000000000822.


Ewing sarcoma is a highly resistant disease with a <10% chance of survival at 5 years after failure of frontline chemotherapy. This is a case report of an Ewing sarcoma patient with metastatic disease recurrence <2 years after standard chemotherapy/radiation who achieved a durable and sustained complete response after 2 series of treatments with Vigil (GMCSF/bi-shRNA furin DNA autologous tumor immunotherapy) serially manufactured from first and second recurrences with ELISPOT assay correlation. Results support justification of further testing of Vigil with ELISPOT assay as a biomarker to assess level of immune response and correlation with disease control.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Benzhydryl Compounds / administration & dosage*
  • Benzhydryl Compounds / therapeutic use
  • Cancer Vaccines / administration & dosage*
  • Cancer Vaccines / therapeutic use
  • Enzyme-Linked Immunospot Assay
  • Female
  • Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use
  • Humans
  • Immunotherapy / methods*
  • Modafinil
  • RNA, Small Interfering / therapeutic use
  • Salvage Therapy / methods
  • Sarcoma, Ewing / diagnosis
  • Sarcoma, Ewing / therapy*
  • Treatment Outcome


  • Benzhydryl Compounds
  • Cancer Vaccines
  • FANG vaccine
  • RNA, Small Interfering
  • Granulocyte-Macrophage Colony-Stimulating Factor
  • Modafinil